Evidence-informed pharmacology monograph updated 10 November 2026. For education only; use current local labeling, clinical guidance and individual assessment.
Overview and structure
Dextromethorphan is a synthetic dextrorotatory morphinan used as a centrally acting nonopioid antitussive at recommended doses. It is structurally related to opioid compounds but has little clinically meaningful mu-opioid agonist activity at usual antitussive exposures. The original description as a piperidine-family chemical and as the (-) isomer of an OTC racemate was incorrect: pharmaceutical dextromethorphan is the (+) enantiomer, not a routine racemic mixture [1,2].
Mechanisms and pharmacokinetics
Dextromethorphan suppresses cough through central neural circuits; exact antitussive receptor-level mechanisms are incompletely defined. It and its metabolite dextrorphan have sigma-1 and NMDA-related activities, particularly at higher exposures. Hepatic CYP2D6 converts dextromethorphan to dextrorphan, while CYP3A4 also contributes to metabolism. CYP2D6 poor metabolizers or patients taking potent CYP2D6 inhibitors can have markedly higher parent-drug exposure, changing adverse effects and interactions [1,2].
Appropriate indications and limits
Short-term treatment may be reasonable for troublesome dry cough associated with self-limited upper respiratory infections, although benefit in acute viral cough is variable and often modest. Evaluate persistent cough, shortness of breath, fever, hemoptysis, weight loss or suspected asthma/ACE-inhibitor-associated cough rather than reflexively suppressing symptoms. Product age restrictions and combinations vary by country and formulation [1].
Interactions and toxicity
Serotonin toxicity may occur with MAO inhibitors, SSRIs, SNRIs, linezolid, tramadol or other serotonergic drugs, especially with overdose or metabolic inhibition. Typical features include agitation, clonus, hyperreflexia, hyperthermia and autonomic instability. Misuse at high doses can cause dissociation, hallucinations, hypertension, agitation, seizures and dangerous intoxication. Some combination cough remedies add sedating antihistamines, paracetamol or decongestants and carry their own overdose risks [1,2].
Dextromethorphan–bupropion is a different product
The fixed combination dextromethorphan/bupropion is a prescription medication with a distinct evidence base and safety profile from over-the-counter cough syrup. Bupropion inhibits CYP2D6, deliberately increasing dextromethorphan exposure; the combination has antidepressant-related indications under US labeling and warnings for seizures, hypertension, manic activation and suicidal thoughts in younger patients. Do not transfer dosing or indications between formulations [2].
Practical precautions
Avoid self-medicating chronic or unexplained cough. Follow product age limits and label directions, assess interactions before combining with antidepressants, and seek urgent evaluation for suspected serotonin toxicity or overdose [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets: prescribing information, revised 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.